Literature DB >> 6147153

Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function.

J M Hunter, R S Jones, J E Utting.   

Abstract

Vecuronium (initial dose 0.1 mg kg-1; incremental doses 0.04 mg kg-1) was given to 21 normal and 21 anephric patients. There were no gross differences between the two groups in the effect or in the duration of action of either initial or incremental doses, except in two anephric patients who were resistant to the agent. Reversal with neostigmine was satisfactory. In normal patients the initial dose of vecuronium was slower in onset of action than was atracurium 0.5 mg kg-1 (26 patients): the first two incremental doses of vecuronium were administered significantly earlier than the corresponding increments of atracurium (0.2 mg kg-1), but the duration of action of increments over-all was not greatly different. However, in anephric patients, except in the resistant patients, the behaviour of vecuronium was similar to that of atracurium (26 patients). A comparison with an initial dose of tubocurarine 0.5 mg kg-1 given to 20 anephric patients and tubocurarine 0.6 mg kg-1 given to 21 normal and 20 anephric patients showed tubocurarine to be longer acting and considerably less predictable. This was particularly so in the anephric group, in which its action sometimes persisted after neostigmine had been given.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147153     DOI: 10.1093/bja/56.9.941

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  12 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.

Authors:  L H Booij
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

3.  Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.

Authors:  R H Vandenbrom; J M Wierda; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Anaesthesia for renal transplantation in sickle cell disease.

Authors:  H K Gyasi; A W Zarroug; M Matthew; R Joshi; A Daar
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

Review 5.  Atracurium and laudanosine pharmacokinetics in acute renal failure.

Authors:  J M Hunter
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

6.  Secondary hyperparathyroidism shortens the action of vecuronium in patients with chronic renal failure.

Authors:  K Takita; Y Goda; O Kemmotsu; H Mashio; A Okuyama; Y Ito; H Sakamoto; H Kawahigashi
Journal:  Can J Anaesth       Date:  1995-05       Impact factor: 5.063

7.  A prospective randomized double blind study to evaluate the effect of infusion of amino Acid enriched solution on recovery from neuromuscular blockade.

Authors:  Nishkarsh Gupta; Raminder Sehgal; Rakesh Kumar; Kavita Rani Sharma; Anju Gupta; Nidhi Agrawal
Journal:  Indian J Anaesth       Date:  2009-06

Review 8.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

Review 9.  The use of muscle relaxants in the intensive care unit.

Authors:  M D Sharpe
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

10.  Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.

Authors:  A Sidi; R F Kaplan; R F Davis
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.